Boston Scientific announces planned board director departure

Boston Scientific ( (BSX) ) has shared an announcement.

On February 2, 2026, Boston Scientific announced that long-serving director Yoshiaki Fujimori, who joined the board in July 2016 and currently chairs the Risk, Science and Technology Committee, has informed the company he will not stand for re-election at the 2026 Annual Meeting of Stockholders, though he will continue in his roles until that meeting. The company emphasized that Fujimori’s decision was not due to any disagreement with Boston Scientific, and the board, together with its Nominating and Governance Committee, will continue to assess its size and composition and consider whether adding new directors after his departure is in the best interest of the company and its stakeholders.

The most recent analyst rating on (BSX) stock is a Buy with a $100.00 price target. To see the full list of analyst forecasts on Boston Scientific stock, see the BSX Stock Forecast page.

Spark’s Take on BSX Stock

According to Spark, TipRanks’ AI Analyst, BSX is a Neutral.

The score is driven by strong financial performance and upbeat 2026 guidance with continued growth, margin expansion, and free-cash-flow strength. These positives are partially offset by weak technical momentum (below key moving averages with negative MACD) and a high P/E valuation that offers limited margin of safety.

To see Spark’s full report on BSX stock, click here.

More about Boston Scientific

Boston Scientific Corporation is a global medical device company that develops and manufactures products used in a wide range of interventional medical specialties, including cardiology, endoscopy and other minimally invasive procedures, serving hospitals and healthcare providers worldwide.

Average Trading Volume: 11,631,569

Technical Sentiment Signal: Hold

Current Market Cap: $112B

For an in-depth examination of BSX stock, go to TipRanks’ Overview page.